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Abstract
In recent years, tyrosine kinases (TKs) have been recognized as central players and regulators of cancer cell 
proliferation, apoptosis, and angiogenesis, and are therefore considered suitable potential targets for anti-cancer 
therapies. Several strategies for targeting TKs have been developed, the most successful being monoclonal antibodies 
and small molecule tyrosine kinase inhibitors. However, increasing evidence of acquired resistance to these drugs has 
been documented, and extensive preclinical studies are ongoing to try to understand the molecular mechanisms by 
which cancer cells are able to bypass their inhibitory activity.
This review intends to present the most recently identified molecular mechanisms that mediate acquired resistance to 
tyrosine kinase inhibitors, identified through the use of in vitro models or the analysis of patient samples. The 
knowledge obtained from these studies will help to design better therapies that prevent and overcome resistance to 
treatment in cancer patients.
Introduction
The most common type of pharmacological anticancer
treatment has been, for decades, conventional chemo-
therapy. This type of treatment does not discriminate
between rapidly dividing normal cells and tumor cells,
thus leading to severe systemic side effects, while
attempting to reduce the tumor mass. In the last decade,
the use of novel molecular targeted therapies has raised
interest of both patients and clinicians. These treatments
inhibit specific molecules that have a role in tumor
growth or progression, and that are frequently altered in
tumors but not in normal cells; thus, being more specific
toward tumor cells, they are accompanied by reduced
systemic toxicity [1]. Nowadays, targeted therapies repre-
sent an integrative approach to cancer therapy that has
already led to important clinical results [2,3].
Tyrosine Kinases
Tyrosine kinases have been identified as signaling mole-
cules and prototypic oncogenes, and shown to play an
important role in the development of many diseases,
including cancer [4]. There is strong evidence that during
tumor progression, the hyperactivation of tyrosine
kinases leads to the continuous activation of downstream
signaling cascades that block cellular apoptosis, promote
cellular proliferation, and increase the nutrient/waste
interchange by enhancing angiogenesis.
Receptor Tyrosine Kinases (RTKs) are single pass trans-
membrane proteins that account for almost two thirds of
the genes coding for tyrosine kinases. RTKs possess a
common functional kinase domain that is able to trans-
late extracellular signals into active intracellular cues.
Under physiological conditions, these receptors are acti-
vated only upon ligand binding [5]. Activation of the
kinase is achieved by ligand-binding to the extracellular
domain, which induces homo/hetero-dimerization of the
receptors [6]. Activated receptors phosphorylate tyrosine
residues outside their catalytic domain via cross-phos-
phorylation. This phosphorylation stabilizes the receptor
conformation in an active state and creates phosphoty-
rosine docking sites for proteins which transduce signals
within the cell [7,8].
In cancer, this mechanism of ligand-dependent activa-
tion can be bypassed by (i) overexpression of the RTK,
which increases the dynamics of receptor homo/het-
erodimerization in the absence of the ligand [9-11]; (ii) by
activating mutations, which stabilize the receptor active
conformation [12]; or (iii) by autocrine stimulation.
These mechanisms lead to cell autonomous activation of
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RTKs that drive proliferative and anti-apoptotic signals,
contributing to transformation [7].
Non-Receptor Tyrosine Kinases (NRTKs), the second
class of TKs, account for the remaining third of the
approximately 90 known TKs and are critical signal
transducers. Some examples include the well-known and
well-characterized NRTKs Src, JAK, c-Abl and FAK.
Interestingly, NRTKs were the first tyrosine kinases dis-
covered [13-16]. Their involvement in cancer can occur
through various mechanisms such as overexpression,
mutation, and translocation; and therefore, many com-
pounds have been developed attempting to inhibit their
activity [17].
Treatments with tyrosine kinase inhibitors (TKIs), in
some cases, have given promising results. However, most
tumors treated with TKIs became resistant to treatment
in a short time [18]. In other words, just as bacteria
develop resistance to antibiotics, neoplastic cells can
acquire new traits that render them more aggressive and
able to survive in the presence of molecular inhibitors.
Clinical experience has shown that only a percentage of
patients respond to targeted therapies, even if their
tumor expresses the altered target. This primary resis-
tance to treatment is often due to constitutive activation
of downstream signal transducers [19-21]. Recently,
many reports have evidenced that patients carrying acti-
vating mutations in effectors downstream of the targeted
molecule account for the majority of the non-responsive
patients [22,23].
Given that many patients are starting to benefit from
tyrosine kinase inhibitors, including monoclonal antibod-
ies and small molecule inhibitors, clinicians and basic
researchers are now trying to unveil and understand the
mechanisms through which neoplastic cells loose their
ability to respond to these drugs (also known as second-
ary resistance or acquired resistance). Luckily, it appears
that the majority of the resistance models developed in
vitro are predictive of what is observed in vivo and can
thus help researchers in identifying and studying this cru-
cial clinical problem.
This review will attempt to provide an updated com-
pendium of cellular modifications that contribute to
acquired resistance to TKIs, highlighting the importance
of preclinical studies of these drugs.
Targeting Tyrosine Kinases
Many research groups, including ours, have shown that
the inhibition of RTKs in neoplastic cells - by administra-
tion of monoclonal antibodies, interfering RNAs, and/or
small kinase inhibitors (TKIs) - impairs cell proliferation
and survival, inducing arrest of cell growth and apoptosis
[24-28]. Based on these findings, many pharmaceutical
companies have invested in designing or identifying new
methods of inhibiting tyrosine kinases.
Small molecule tyrosine kinase inhibitors
Pharmaceutical companies have focused their research
on the development of small TKIs, some of which have
received the approval of governmental drug administra-
tion agencies. Additional file 1 lists some TKIs currently
approved or undergoing clinical trials. TKIs are small
molecules that inhibit the enzymatic activity of the target
protein. Most of these molecules can be categorized into
four groups: (i) ATP-competitive inhibitors, which bind
predominantly to the ATP-binding site of the kinase
when this site is in the active conformation; (ii) inhibitors
that recognize and bind to the non-active conformation
of the ATP-binding site of the kinase, thus making activa-
tion energetically unfavorable; (iii) allosteric inhibitors,
that bind outside of the ATP-binding site, modifying the
tridimensional structure of the receptor and disrupting
the interaction between the ATP and the kinase pocket;
and (iv) covalent inhibitors, that bind irreversibly by
covalently bonding to the ATP-binding site of the target
kinase (reviewed in [29]).
While monoclonal antibody (mAb) therapy is particu-
larly suited for extracellular (membrane-bound or
secreted) targets, small-molecule kinase inhibitors are
effective against both membrane-bound and intracellular
targets. While both therapies have advantages and disad-
vantages when compared to each other, the major differ-
ences between monoclonal antibodies and small TKIs are
the modality of administration, the bioavailability and
half-life, and the mechanisms of resistance to the thera-
peutic agents [30-32]. (See comparison table 1).
Monoclonal Antibodies
Immunotherapy is based on the production of human-
ized monoclonal antibodies (mAbs) that bind with high
specificity to secreted proteins or to the extracellular
domain of membrane-bound proteins. The use of mAbs
relies on the principle that most of the targeted molecules
are expressed at higher levels on neoplastic cells, when
compared to normal cells, where they play an important
role in sustaining cancer progression. So far, there are
several mechanisms described by which they exert their
therapeutic effects; among them are: binding to the
ligand or to the receptor, thus preventing ligand-receptor
interaction [33,34]; disrupting receptor internalization
[35], promoting receptor internalization [36], shedding of
the extracellular portion of the receptor [36,37], prevent-
ing receptor dimerization and activation [38], and induc-
tion of apoptosis [39,40]. However, it is believed that each
mAb acts through more than one mechanism. In addi-
tion, evidence has shown that activation of the immune
response against the targeted tumor cells, upon recogni-
tion of the bound antibody, can also account for their bio-
logical activity [41]. Table 2 lists monoclonal antibodiesSierra et al. Molecular Cancer 2010, 9:75
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directed again tyrosine kinases currently used in preclini-
cal and clinical studies.
Monoclonal antibodies have been widely used in the
clinic and have shown promising results, but unfortu-
nately many patients relapse due to development of
mechanisms of resistance. Information obtained from
cellular models and relapsed patients has provided
insights on how cells adapt to the treatment, by reducing
the expression or modifying the structure of the target
protein or activating alternative survival pathways [42].
Mechanisms of resistance to TKIs
Genetic modifications
Clinical and in vitro evidence have shown that cells
treated with TKIs tend to acquire genetic modifications
to overcome the inhibitory effects of these agents. Com-
mon mechanisms of resistance include, but are not lim-
ited to: point mutations, deletions and amplifications of
genomic areas. A schematic summary of the main molec-
ular mechanisms of acquired resistance to small mole-
cules is represented in Figure 1.
Mutations
Mutations are common and occur frequently in rapidly
dividing cancer cells. Point mutations are the most com-
mon mechanism of resistance to TKIs. The most fre-
quent types of mutations are those that decrease the
affinity of the drug for the target kinase domain, while
maintaining its catalytic activity. Other mutations alter
the amino acids surrounding the binding site of the drug
and decrease the availability of the target region towards
the inhibitor, without interfering with ATP binding [29].
Finally, some mutations increase the affinity of the kinase
for ATP, decreasing the effectiveness of the ATP-compet-
itive inhibitors [43].
The strongest evidence comes from imatinib, a small
tyrosine kinase inhibitor that was found to bind with high
affinity to c-Abl kinase. Imatinib is used to treat Chronic
Myeloid Leukemia (CML) patients who express a consti-
tutively active c-Abl tyrosine kinase, the BCR-ABL fusion
protein. Imatinib abrogates the oncogenic function of
BCR-ABL by binding the protein in its inactive state, thus
preventing its autophosphorylation and, therefore, block-
ing the activation of downstream signal transducers. The
use of imatinib has improved the life expectancy of CML
patients, but major concerns have been raised for this and
other TKIs by the rapid development of mechanisms of
resistance. The majority of the CML patients in advanced
stage (66%) and some in the chronic phase (5%) relapse
after imatinib treatment, developing c-Abl dependent
and independent mechanisms of resistance [44]. Approx-
imately 30-50% of the relapsed patients acquire point
mutations (around 90 distinct point mutations identified
so far) that change the conformation of the c-Abl kinase,
reducing or abrogating the ability of the compound to
Table 1: Major differences between monoclonal antibodies and small molecule tyrosine kinase inhibitors.
mAb Small molecule TKI
Administration Intravenous Oral or parenteral
Target availability Must be extracellular Extra/intra-cellular
Cost US$ 4,200/month (trastuzumab) US $1,800/month (gefitinib)
Size ~150,000 daltons ~400 daltons
Diffusion Near vessels, surrounding tumor area; 
inefficient delivery
Easy to diffuse, translocate though plasma 
membranes, may reach brain tissues
Toxicity Low toxicity Mid-high toxicity
Half-Life Days-weeks <72 h
Mechanism of Action Disrupt ligand-receptor or receptor-
receptor (homo/hetrodimerization)
interactions, receptor downregulation, 
induction of apoptosis
Bind to target kinase(s), inhibit 
phosphorylation and downstream 
signaling pathways. Induce apoptosis.
Approval success rate 18-24% 5%
Mechanisms of resistance Protein Modifications:
Switch of surface receptors.
Shedding of the extracellular portion of 
the receptor.
Expression of truncated receptors.
Modification of receptor structure.
Activation of downstream signaling 
pathways.
Genetic modifications:
Point Mutations (Activating mutations).
Amplifications (Target gene).
Deletions.
Protein Modifications:
Overexpression of the target protein.
Activation of alternative pathways.
Overexpression of Multidrug resistance 
genes.Sierra et al. Molecular Cancer 2010, 9:75
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bind the c-Abl kinase domain [45-47]. This molecular
mechanism of resistance has been supported also by
structural studies which have shown that imatinib cannot
efficiently interact with the ATP binding pocket in the
mutated forms of BCR-ABL. When reports started to
show that mutations in the kinase domain of c-Abl were
present in relapsed patients, and experimental work
showed that the mutant kinase was no longer inhibited by
imatinib, second generation inhibitors, such as dasatinib
[48], nilotinib [48,49], sunitinib [50], and bosutinib [51]
were designed. These new molecules are able to recog-
nize and bind BCR-ABL in different conformations, and
are thus suitable for imatinib-relapsed patients. Dasatinib
and nilotinib are able to interact with most of the
mutated imatinib-resistant c-Abl forms, with the excep-
tion of the T315I mutant that changes the kinase and
modifies several contact points between the drug and the
kinase, while preserving the kinase activity [43,52,53].
The only inhibitor so far that has been proven to inhibit
this mutant is the multikinase inhibitor KW-2449 [54].
However, CML patients who used these second genera-
tion inhibitors developed resistance by acquiring new
mutations in the kinase domain [55].
Why do patients develop these mutations during treat-
ment? There are reports that support the idea that the
appearance of mutations in tumors after treatment with a
specific TKI is the result of a process of selection of a pre-
existing cell population. This theory implies that a small
population of the tumor bulk a priori contains the muta-
tion, which confers a primary resistance to these cells,
therefore giving them a selective advantage. The bulk
tumor mass is thus killed by the drug, allowing cells resis-
tant to the TKI to grow. This theory is supported by the
fact that some of these "resistance related mutations" can
be found in a small percentage of tumor cells in patients
that have not yet undergone targeted therapy [56-59]. On
the other hand, other researchers believe that the high
d e p e n d e n c e  o f  a  c e l l  o n  a  s p e c i f i c  o n c o g e n i c  s u r v i v a l
pathway forces genomic instability, allowing the induc-
tion of mutations that confer resistance to the inhibitor.
This genomic instability can induce mutations either in
the drug target or in other signal transducers that activate
alternative pathways able to sustain cell viability. This
Table 2: List of Monoclonal antibodies approved by FDA or undergoing clinical trials.
Name of mAb Commercial Name Approval Year Target Kinase Mechanism of 
resistance
Bevacizumab 
(Genentech/Roche)
Avastin 2004 VEGFR 4
Cetuximab (ImClone 
and Bristol-Myers 
Squibb)
Erbitux 2004 EGFR 1,2,3,4
Panitumumab 
(Amgen)
Vectibix 2006 EGFR
Trastuzumab 
(Genentech)
Herceptin 1998 ERBB2 2,4,5
IMC-A12 
Cixutumumab
(ImClone)
Phase II IGF1-R
AVE1642
(Sanofi-Aventis)
Phase I IGF1-R
Pertuzumab
(Genentech)
Omnitarg Phase III ERBB2
MetMAb
(Genentech)
Phase I/II MET
IMC-1121B 
Ramucirumab
(ImClone)
Phase III VEGFR-2
IMC-18F1
(ImClone)
Phase I VEGFR
AMG-102 
Rilotumumab (Amgen)
Phase II MET
Antibodies common name is followed by () that denotes producer. Mechanisms of resistance: 1) overexpression of alternative RTK, 2) 
expression of receptor variants, 3) overexpression of target protein, 4) developed new signaling pathways, 5) structure modificationSierra et al. Molecular Cancer 2010, 9:75
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theory has been supported by groups who have induced
r e s i s t a n c e  t o  T K I s  i n  i m a t i n i b - s e n s i b l e  C M L  c e l l  l i n e s
cloned by limiting dilution; they have found the appear-
ance of BCR-ABL gene amplification and of point muta-
tions in the kinase domain that were not present in the
original cells [60].
Further studies revealed that imatinib also binds with
high affinity to the cKIT and PDGFR kinases, frequently
activated in Gastrointestinal Stromal Tumors (GIST)
[61]. GISTs are the first solid tumors in which a tyrosine
kinase inhibitor was used as standard care. As these
tumors often display mutations in the tyrosine kinase
receptors cKIT and PDGFR, imatinib was used to inhibit
their activity [62]. Like CML patients, 50-70% of GIST
patients treated with imatinib develop secondary muta-
tions within the cKIT gene, conferring a reduced drug
binding affinity but still retaining the kinase activity
[63,64]. To suppress the kinase activity of the resistant
cKIT mutants, sunitinib was developed. As previously
observed in patients treated with other inhibitors of sec-
ond generation, imatinib-resistant GIST patients treated
with sunitinib developed new mutations that made them
again resistant to the new drug [65].
Gefitinib and erlotinib are small molecule TKIs target-
ing the Epidermal Growth Factor Receptor (EGFR) that
have been used to treat tumors where this RTK is known
to be altered. In particular, they have been used to treat
non-small cell lung carcinomas (NSCLC) where EGFR is
frequently overexpressed or activated due to point muta-
tions [66]. According to a compendium of studies that
include 1170 patients, more than 70% of NSCLCs with
EGFR mutations respond to EGFR-TKIs, whereas only
10% of tumors without EGFR mutations do so. Unfortu-
nately, upon treatment of these patients with gefitinib
and erlotinib, two major mechanisms of resistance have
been observed. The first is the appearance of a "resis-
tance" point mutation in the kinase domain (T790M),
observed in 50% of the gefitinib-resistant patients [67].
This mutation increases the affinity for ATP and weakens
the affinity for ATP-competitive inhibitors [22,68]. On
the other hand, the second mechanism is the activation of
an alternative oncogene able to compensate for the inhib-
ited signaling pathways [69,70].
Interestingly, in vitro models of acquired resistance to
gefitinib, obtained by exposing gefitinib-sensitive cells to
increasing concentrations of the drug, led to the appear-
ance of the same mutations identified in patients. This
has allowed scientists to study the mechanisms through
which these mutations modulate sensitivity to the drug
[71-75]. Lapatinib is another EGFR inhibitor, recently
approved for treatment of breast cancer. This inhibitor
has been designed to block receptor signaling by binding
to the ATP-binding pocket of EGFR and ERBB2 kinase
domains, thus preventing phosphorylation and subse-
quent downstream signaling from these two receptors
[76]. Using a randomly mutagenized ERBB2 library in
vitro, Trowe et al. were able to identify 12 mutations in
the kinase domain of ERBB2 that could confer resistance
to the inhibitor [77]. Moreover, this same work showed
that a new generation inhibitor, EXEL-7647, is still active
on all the mutants.
Similarly, activating mutations in the FLT3 RTK occur
frequently in Acute Myelogenous Leukemia (AML).
When AML patients were treated with PKC412, a stauro-
sporin derivative able to inhibit FLT3's kinase activity,
patients rapidly developed point mutations in the kinase
domain of FLT3 that rendered the kinase less accessible
to the inhibitor [78]. These same mutations had been pre-
viously foreseen by a computational predictive analysis
and confirmed by in vitro data when Cools et al. identi-
fied possible mutations in residues conferring a high level
of resistance to small molecules [79]. Recently, another
cellular model has predicted new point mutations that
confer resistance to FLT3 inhibitors such as SU5614,
PKC412, and sorafenib. As the different FLT3 kinase
inhibitors generated distinct, non-overlapping muta-
tional profiles, the authors propose that a combination of
FLT3 inhibitors might be useful to prevent the appear-
ance of FLT3 resistance mutations [80].
As previously mentioned, another clinically approved
TKI currently in use is sorafenib. This small molecular
multikinase inhibitor, primarily targets BRAF and can
inhibit several other TKs such as PDGFR, VEGFR 1-2,
FLT3, and cKIT [81]. This multi-target drug possesses
anti-tumoral and anti-angiogenic properties due to its
broad blocking activity. The use of sorafenib, just as with
other small molecule inhibitors, has caused so far a vari-
ety of mutations in PDGFR [82], FLT3 [80], and BRAF
[83] that confer resistance to the treatment.
Figure 1 Schematic summary of the main molecular mechanisms 
of acquired resistance to TKIs.
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Gene Amplification
Gene amplification is a major mechanism of oncogenic
activation [84]. Preclinical and clinical data have shown
that the presence of either activating mutations in the
kinase domain or gene amplification correlate with the
best response to TKI [84,85]. Unfortunately, the selective
pressure of the drug can drive further amplification of the
target gene, thus leading to additional overexpression of
the encoded protein. This idea originates from in vitro
studies that have shown that highly amplified oncogenes
are located in extrachromosomal acentromeric double
minutes, and such cells undergoing "oncogenic stress"
may undergo further gains due to advantageous unsym-
metrical nuclear division [86]. These gains alter the stoi-
chiometry of the drug-target interaction in favor of the
target and result in its inefficient inhibition. This event
has been observed in CML relapsed patients treated with
imatinib, who displayed an increase in the BCR-ABL gene
copy number [87]. In these patients, an increase in drug
dosage is usually sufficient to restore responsiveness to
the treatment. This same mechanism of resistance had
been observed in an in vitro model where a CML cell line
was treated for a long period of time with imatinib [42].
Likewise, the emergence of amplification of the target
gene as a mechanism of resistance has been observed in
two other cases where resistance cells amplified EGFR
[88] or FTL3 [89] in response to inhibitors.
Another way through which gene amplification can
mediate resistance to treatment is via amplification of
genes that encode for critical transducers driving signal-
ing pathways that can compensate for the signals lost due
to target inhibition [69]. A notable example is the amplifi-
cation of the MET  gene, encoding for the receptor
tyrosine kinase for hepatocyte growth factor, in a per-
centage of gefitinib-relapsed patients affected by NSCLC.
These results perfectly correlated with those obtained in
in vitro studies after treating sensitive NSCLC cell lines
with progressively increasing doses of gefitinib or other
EGFR inhibitors [57,58,70,90,91]. In these experiments,
MET overexpression led to its constitutive activation by a
ligand-independent mechanism, which later resulted in
advantageous interactions with other EGFR family mem-
bers, mainly ERBB3, and activation of downstream sig-
n a l s .  I n h i b i t i o n  o f  M E T ,  i n  t h i s  c o n t e x t ,  r e s t o r e d
sensitivity to EGFR inhibitors [70].
Genomic Deletions
Other genomic alterations frequently observed upon TKI
treatment are deletions. Khorashad and collaborators
performed a genome-wide study comparing DNA sam-
ples from CML patients prior to imatinib treatment and
after relapse. CGH analyses for all patients revealed that
28% of the copy number alterations were genomic dele-
tions. Among the genes that were most frequently altered
were those involved in the control of the MAPK signaling
pathway [92].
Among the genes that are frequently deleted in human
cancers are those encoding microRNAs (miRNAs). MiR-
NAs have emerged as a novel class of regulatory genes
involved in human cancer [93,94]. Lacking the ability to
encode a protein, these single-stranded miRNAs bind to
imperfectly complementary sequences of encoding
mRNAs, causing these mRNA sequences to be silenced
or degraded, resulting in reduced levels of the protein
encoded by the mRNA. Many reports have highlighted
the relevance of these non-coding RNA's in human can-
cer, where they are frequently altered, more often as con-
sequence of their deletion [95]. Various groups have
reported cases where the deletion of miRNA regions has
led to overexpression of the targeted RTKs, due to lack of
down-regulation [95-97]. In this context, Seike and col-
laborators recently correlated high EGFR activation with
high expression of mir-21 both in NSCLC patient sam-
ples and cell lines. They report that inhibition of EGFR by
the small molecule AG1478 reduced the levels of this
miRNA, concluding that the activation status of the
receptor modulates the expression of this anti-apoptotic
miRNA [98]. As it considered a growing field of interest,
various groups have reported that miRNA expression can
mediate resistance to different types of chemotherapy
[99-102] (reviewed in [103]), and it is very likely that quite
soon miRNAs will also be found to play a role in mediat-
ing resistance to TKIs.
Modifications of protein expression
Cells seem to possess a broad repertoire of adaptive reac-
tions that enable them to survive in many adverse condi-
tions. One of the adaptive traits is the overexpression or
the repression of genes that sustain cell viability [104].
Mahon et al. recently demonstrated that nilotinib-resis-
tant CML cell lines were able to upregulate the expression
of BCR-ABL, thus overcoming the inhibitory threshold of
nilotinib [105]. Although this and other similar works
lack evidence that the overexpression of the target pro-
tein is not due to gene amplification (also known mecha-
n i s m  o f  r e s i s t a n c e  t o  B C R - A B L  T K I ) ,  t h i s  c a n  b e
considered as a new mechanism of resistance.
This last response does not involve genetic alterations,
but simply changes in gene expression, due to microenvi-
ronmental stress or to epigenetic modifications. It is
known that the use of TKIs can lead to reduced blood
flow, which in turn increases the incidence of hypoxic
areas [106]. Moreover, hypoxia is known to upregulate
HIF-1a, a protein that can promote the expression of
many genes including the RTK MET, which is capable of
sustaining the MAPK and PI3K survival pathways [107].
Likewise, epigenetic changes can also contribute to TKI
resistance. For example, Noro et al. reported an in vitroSierra et al. Molecular Cancer 2010, 9:75
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model where lung cancer cells resistant to gefitinib dis-
played hypermethylation of the PTEN gene promoter;
exogenous re-expression of this enzyme restores senstiv-
ity to the EGFR inhibitor [108].
Activation of alternative pathways
Some cells can replace the lack of signal due to target
inhibition by activating alternative pathways. The EGFR
family of receptors has been shown to develop mecha-
nisms of resistance by modifying the expression of several
downstream effectors. For example, Pandya and collabo-
rators developed a cellular model where colorectal carci-
noma HCT116 cells, which depend on ERBB2 activity,
lose their sensitivity to lapatinib. The major mechanism
of resistance observed was the increased expression of
MCL-1, and the decreased expression and activity of
BAX and BAK [109], altogether leading to decreased
apoptotic responses. Another proposed mechanism of
resistance was reported by Xia et al. who showed that
lapatinib-resistant breast cancer cells and lapatinib-
treated patients displayed an increased level of the Estro-
gen Receptor and the transcription factor FoxoA3 [110].
Another example was recently reported by Turke et al.
where EGFR-dependent cells stimulated with MET's
ligand, HGF, were resistant both in vivo and in vitro, and
such effect could be blocked by the use of MET inhibitors
[57]. In a similar manner, McDermott et al. reported that
MET-dependent NSCLC cells activate EGFR as a mecha-
nism of resistance to PF2341066 (an irreversible MET
kinase inhibitor) using an increasing dose resistant cellu-
lar model [111].
Another mechanism of resistance that was reported in
NSCLC patients and in cell lines resistant to gefitinib
treatment is the cross-talk between the EGFR/ERBB2
receptors and the IGF-1R receptor [112-114]. This mech-
anism of resistance relies on the fact that cells utilize IGF-
1R to activate survival pathways that are able to promote
growth [115]. One report shows that a prostate cancer
cell line which became resistant to gefitinib displayed an
increase of IGFII mRNA and IGF-1R protein phosphory-
lation [112,113]. Moreover, it was also published that a
gefitinib-resistant lung squamous carcinoma cell line lost
the production of IGFBP3-4 when compared to the
parental cells; re-expression of these proteins restored the
sensitivity to gefitinib's cytostatic effect [116].
The activation of an alternative kinase is known to
overcome the inhibitory effects of small molecules. For
example, GIST cells resistant to imatinib exhibited
increased levels of the AXL receptor, that could in turn
activate the AKT pathway and thus overcome c-KIT inhi-
bition [97,117]. Two different groups have recently shown
that in a cellular model of CML, TKI-resistant cells dis-
play activation of the Src kinase LYN; inhibition of this
kinase by the use of dasatinib restores sensitivity to ima-
tinib or nilotinib [105,118].
In a similar manner, the human myelomonoblastic cell
line MV4-11, generated to be resistant to PKC412, dis-
played an up-regulation of anti-apoptotic genes and
down-regulation of proapoptotic signals as well as genes
that are involved in normal and malignant hematopoiesis
[89].
Recently, Huang et al. reported that tumor xenografts
resistant to sunitinib secreted higher amounts of IL-8
(proangiogenic factor known to be induced by several key
regulators of cell survival and hypoxia) which at the same
time positively correlated with a higher tumor vessel den-
sity [119,120].
Another commonly observed mechanism of resistance
to TKI is the overexpression of survivin a member of the
inhibitor of apoptosis family, encoded by the BIRC5 gene
[110,121]. This cancer therapy candidate gene is overex-
pressed in a large variety of human tumors [122-125] and
its expression is absent in terminally differentiated
[126,127]. Survivin is known to inhibit caspase activation,
and therefore, leading to negatively regulate apoptosis or
programmed cell death, and it has been correlated with
both accelerated relapse and chemotherapy resistance
[128]. Xia et al. have demonstrated that overexpression of
surviving can mediate resistance to lapatinib; such find-
ing was observed by generating lapatinib-resistant breast
cancer cells in vitro and correlating clinical observations
[110].
Mechanisms of Resistance related to drug influx/efflux
There are many mechanisms implicated in the decrease
of the effective intracellular concentration of a drug, lead-
ing to lack of response to treatment. Among the most
important resistance mechanisms are: increased drug
influx/efflux and drug plasma sequestration. Other fac-
tors that can contribute to decreased drug delivery to
tumors include irregular blood flow, defects in the struc-
ture and permeability of tumor vasculature and drug dif-
fusion in the interstitium.
The occurrence of multidrug resistance (MDR) is a very
frequent cause of failure of chemotherapeutic treatment
in cancer patients. MDR proteins are transmembrane
pumps responsible for the active efflux of a broad range
of structurally unrelated molecules. This efflux can occur
despite considerable concentration gradients at the
expense of ATP depletion, resulting in decreased intracel-
lular drug accumulation [129]. It is conceivable that TKIs
may inhibit the function of ATP-binding cassette (ABC)
transporters by recognizing their ATP-binding sites. In
fact, some of these small molecules such as cediranib,
lapatinib, and sunitinib have proven to be effective in
reversing MDR associated to chemotherapeutics, by
directly inhibiting the transport function of some ABCSierra et al. Molecular Cancer 2010, 9:75
http://www.molecular-cancer.com/content/9/1/75
Page 8 of 13
members. This ability renders them useful options for
cancer combinational therapy [130,131]. The initial suc-
cess of molecularly targeted therapies raised hope that
newly developed agents would evade the general mecha-
nisms of resistance that have reduced the efficacy of tra-
ditional anticancer drugs. However, ABC transporters
related to MDR have emerged as key factors that regulate
the intracellular concentrations of many small-molecule
inhibitors. Drug transporters may be overexpressed in
cancer cells, reducing intracellular drug concentrations,
and may allow the evolution of point mutations that con-
fer stronger drug resistance [132].
Mahone and collaborators demonstrated that imatinib-
resistant cell lines overexpressed the P-glycoprotein (P-
gp) efflux pump [133]. This concept was reinforced when
imatinib sensitivity was restored when P-gp pumps were
blocked by different inhibitors [134,135], or silenced
using RNAi [136,137]. All this data indicates that P-gp is a
likely candidate contributing to imatinib resistance, and
some in vitro data suggests that this may also be true for
resistance to nilotinib [105]. Dasatinib and sunitinib have
been shown to be a substrate of both efflux proteins,
ABCB1 and ABCG2 [138,139]. ABCG2 has also been
shown to bind gefitinib with high affinity, causing an
active extrusion of the inhibitor and thus preventing its
biological activity [140].
In addition, multiple reports have provided evidence
that deregulation of the organic cation transporter
hOCT1 can impede the influx of imatinib. Using hOCT
inhibitors on different imatinib-sensitive CML cells
caused a reduced uptake of imatinib [141]. This finding
was further supported by clinical data showing that
patients who display a minimal response to imatinib also
express a significantly lower amount of hOCT [142,143].
Therefore, intracellular drug levels depend in part on the
differential expression of influx and efflux transporters,
which are determinants of TKI resistance.
Another method by which tumors bypass the inhibitory
effects of TKI is by the sequestration of such drugs by
plasma proteins, such as the plasma protein-1 acid glyco-
protein (AGP). It has been shown in vitro and in vivo that
AGP binds to imatinib, and this binding decreases ima-
tinib's ability to inhibit c-ABL in a dose-dependent man-
ner [144], findings supported by clinical data [145,146].
Mechanisms of resistance to monoclonal 
antibodies
Although monoclonal antibodies have given very good
results in the clinic, the emergence of resistance is also
frequently observed upon treatment with these agents.
Several mechanisms of resistance have been observed in
preclinical and clinical studies, mostly with antibodies
that have already undergone FDA approval. In the case of
monotherapy, preexistence of mutations in the MAPK or
PI3K signaling pathways is one of the major causes of pri-
mary or intrinsic resistance. In 2009, the American Soci-
ety of Clinical Oncology suggested that metastatic
colorectal cancer (CRC) patients who displayed an altera-
tion in codon 12 or 13 of KRAS should not be considered
for monoclonal therapy [147]. This decision was based on
multiple studies that have shown that activating muta-
tions in KRAS [148-150], PIK3CA [19], BRAF [151] and
loss of expression of PTEN [152-156] correlated nega-
tively with cetuximab or panitumumab response
(reviewed in [157]).
Patients undergoing monotherapy are also prone to
develop secondary or acquired resistance to such treat-
ment. So far, no mAb therapy has given rise to any point
mutation in the target receptor or rearrangements in
genomic regions. The mechanisms described up to now
typically involve variations in protein expression. At least
five modifications of this type have been shown to con-
tribute to resistance to mAbs:
(i) Overexpression and aberrant phosphorylation of
alternative RTKs attempting to overcome the inhibition
of the targeted protein. In 2008, Wheeler et al. generated
NSCLC and HNSCC cetuximab-resistant cell lines, such
resistance was mediated by the increased expression of
ERBB2, ERBB3, and MET which can interact with other
EGFR family members contributing to their activation
[35]. In a similar way, Lu et al. and Shattuck et al. have
shown that cells can overcome trastuzumab inhibition by
the activation of IGF-1R and MET, respectively [114,158-
161].
(ii) The second known protein modification is expres-
sion of receptor variants. Sok and collaborators demon-
strated that a mutant variant of EGFR (EGFRvIII), which
lacks the ligand binding domain, is expressed in more
than 42% of HNSCC. In their experiments, overexpres-
sion of EGFRvIII in HNSCC cells decreased in the inhibi-
tory response to cetuximab [162].
(iii) The third protein modification involves the tar-
geted protein; in this type of resistance, cells display an
increased expression of the target receptor. Reports have
shown that NSCLC cell lines resistant to cetuximab dis-
play an increase in EGFR protein levels due to a defective
deregulation in the degradation pathways [35,163].
(iv) Activation of alternative pathways is another mech-
anism of resistance. It has been observed that cells resis-
tant to either cetuximab or trastuzumab can develop a
dependency on new signaling pathways either by trigger-
ing the same biological effects by interaction with other
EGFR family members [35,164], or by association with
other kinases such as Src [165]. Valabrega et al. reported
that TGFα (an EGFR ligand) overexpression can contrib-
ute to resistance [166]. It is interesting to note that the
overexpression of ligands is not a rare event, since
patients and cell lines resistant to bevacizumab (a VEGFSierra et al. Molecular Cancer 2010, 9:75
http://www.molecular-cancer.com/content/9/1/75
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blocking antibody) cause tumor cells to secrete additional
angiogenic factors (FGF [167], PGF [168], members of the
notch ligand/receptor family [169]) to compensate for the
lack of VEGF signaling [170,171].
Lastly, (v) the lack of interaction between the target and
the mAb due to steric hindrance caused by the formation
of complexes with other cell surface proteins, such as in
the case of resistance to trastuzumab. It is known that the
expression of MUC4, a membrane-associated mucin that
contributes to the masking of membrane proteins,
decreases the amount of trastuzumab that can bind to
ERBB2 [172] When MUC4 was silenced in trastuzumab
resistant cells, cells were once again sensitive to the mAb
[173].
Conclusions
New clinical and laboratory studies have suggested that
multi-targeting approaches against neoplastic cells could
help to increase patient survival and, possibly, reduce the
emergence of cells resistant to single-target inhibitors
[174]. This increased activity will have to be balanced by
the expected increased toxicity due to the association of
the drugs. Moreover, combination mAbs and multi-target
small molecules could be also a very promising therapeu-
tic approach [175,176].
Accumulating experimental and clinical evidences have
supported the idea that targeted therapy should be reas-
sessed. In particular, we should keep in mind that tumors
are the result of multiple genetic lesions. Clinicians and
researchers should not underestimate the capacity of
tumors to easily adapt to new stress conditions, therefore
inducing or selecting those cells that can better survive in
the presence of an inhibitor.
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